Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Camilla Frich Riber is active.

Publication


Featured researches published by Camilla Frich Riber.


Advanced Healthcare Materials | 2015

Self-Immolative Linkers Literally Bridge Disulfide Chemistry and the Realm of Thiol-Free Drugs.

Camilla Frich Riber; Anton A. A. Smith; Alexander N. Zelikin

The ultimate goal of controlled, intracellulardrug delivery is to get the drug to the target cell without spilling the contents in transit and then release the entire payload upon cell entry. One of the most powerful platforms to achieve this relies on the intracellular disulfide reshuffling as a trigger for drug release form the engineered prodrugs. However, utility of disulfide reshuffling for drug release is naturally applicable only to the thiol containing molecules-ultimately leaving nearly all commercialized drugs beyond the scope of this platform. This is a drastic limitation. A cunning new tool of organic chemistry is fast entering the mainstream of prodrug design: the self-immolative linkers. This platform allows overcoming the natural chemical barrier and makes it possible to link virtually any drug to its carrier via a disulfide bond and engineer a specific intracellular release. It is a game-changing accomplishment of modern organic chemistry. The scope and limitations of this novel opportunity for medicinal chemistry and nanomedicine are outlined.


Chemistry: A European Journal | 2017

Preparation, single-molecule manipulation and energy transfer investigation of a polyfluorene-graft-DNA polymer

Mikael Madsen; Rasmus S. Christensen; Abhichart Krissanaprasit; Mette R Bakke; Camilla Frich Riber; Karina S Nielsen; Alexander N. Zelikin; Kurt V. Gothelf

Conjugated polymers have been intensively studied due to their unique optical and electronic properties combined with their physical flexibility and scalable bottom up synthesis. Although the bulk qualities of conjugated polymers have been extensively utilized in research and industry, the ability to handle and manipulate conjugated polymers at the nanoscale lacks significantly behind. Here, the toolbox for controlled manipulation of conjugated polymers was expanded through the synthesis of a polyfluorene-DNA graft-type polymer (poly(F-DNA)). The polymer possesses the characteristics associated with the conjugated polyfluorene backbone, but the protruding single-stranded DNA provides the material with an exceptional addressability. This study demonstrates controlled single-molecule patterning of poly(F-DNA), as well as energy transfer between two different polymer-DNA conjugates. Finally, highly efficient DNA-directed quenching of polyfluorene fluorescence was shown.


Molecular Pharmaceutics | 2016

Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1

Maarten Danial; Anna H.F. Andersen; Kaja Zuwala; Steffen Cosson; Camilla Frich Riber; Anton A. A. Smith; Martin Tolstrup; Graeme Moad; Alexander N. Zelikin; Almar Postma

In this article a library of polymeric therapeutic agents against the human immunodeficiency virus (HIV) is presented. The library of statistical copolymers of varied molar mass was synthesized by reversible addition-fragmentation chain transfer (RAFT) polymerization. The synthesized polymers comprise pendent hydroxyl and sulfonated side chains as well as the reverse transcriptase prodrug lamivudine (3TC) attached via a disulfide self-immolative linker. The glutathione mediated release of 3TC is demonstrated as well as the antiviral efficacy against HIV entry and polymerase activity. Although a high degree of polymer sulfonation is required for effective HIV entry inhibition, polymers with approximately ∼50% sulfonated monomer demonstrated potent kinase independent reverse transcriptase inhibition. In addition, the sulfonated polymers demonstrate activity against DNA-DNA polymerase, which suggests that these polymers may exhibit activity against a broad spectrum of viruses. In summary, the polymers described provide a triple-active arsenal against HIV with extracellular activity via entry inhibition and intracellular activity by kinase-dependent lamivudine-based and kinase-independent sulfonated polymer based inhibition. Since these sulfonated copolymers are easily formulated into gels, we envision them to be particularly suited for topical application to prevent the mucosal transmission of viruses, particularly HIV.


Biomicrofluidics | 2015

Phospholipid-polymer amphiphile hybrid assemblies and their interaction with macrophages.

Karthiga Panneerselvam; Martin E. Lynge; Camilla Frich Riber; Sofia Mena-Hernando; Anton A. A. Smith; Kenneth N. Goldie; Alexander N. Zelikin; Brigitte Städler

Recently, the combination of lipids and block copolymers has become an alternative to liposomes and polymersomes as nano-sized drug carriers. We synthesize novel block copolymers consisting of poly(cholesteryl acrylate) as the hydrophobic core and poly(N-isopropylacrylamide) (PNIPAAm) as the hydrophilic extensions. Their successful phospholipid-assisted assembly into vesicles is demonstrated using the evaporation-hydration method. The preserved thermo-responsive property of the lipid-polymer hybrids is shown by a temperature dependent adsorption behaviour of the vesicles to poly(l lysine) coated surfaces. As expected, the vesicle adsorption is found to be higher at elevated temperatures. The cellular uptake efficiency of hybrids is assessed using macrophages with applied shear stress. The amount of adhering macrophages is affected by the time and level of applied shear stress. Further, it is found that shorter PNIPAAm extensions lead to higher uptake of the assemblies by the macrophages with applied shear stress. No inherent cytotoxicity is observed at the tested conditions. Taken together, this first example of responsive lipid-polymer hybrids, and their positive biological evaluation makes them promising nano-sized drug carrier candidates.


Molecular Pharmaceutics | 2017

Macromolecular Prodrugs of Ribavirin: Structure–Function Correlation as Inhibitors of Influenza Infectivity

Camilla Frich Riber; Tracey M. Hinton; Paulina Gajda; Kaja Zuwala; Martin Tolstrup; Cameron R. Stewart; Alexander N. Zelikin

The requirement for new antiviral therapeutics is an ever present need. Particularly lacking are broad spectrum antivirals that have low toxicity. We develop such agents based on macromolecular prodrugs whereby both the polymer chain and the drug released from the polymer upon cell entry have antiviral effects. Specifically, macromolecular prodrugs were designed herein based on poly(methacrylic acid) and ribavirin. Structure-function parameter space was analyzed via the synthesis of 10 polymer compositions varied by molar mass and drug content. Antiviral activity was tested in cell culture against both low and high pathogenic strains of influenza. Lead compounds were successfully used to counter infectivity of influenza in chicken embryos. The lead composition with the highest activity against influenza was also active against another respiratory pathogen, respiratory syncytial virus, providing opportunity to potentially treat infection by the two pathogens with one antiviral agent. In contrast, structure-function activity against the herpes simplex virus was drastically different, revealing limitations of the broad spectrum antiviral agents based on macromolecular prodrugs.


Advanced Healthcare Materials | 2017

Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses

Franziska Schandock; Camilla Frich Riber; Annika Röcker; Janis A. Müller; Mirja Harms; Paulina Gajda; Kaja Zuwala; Anna H. F. Andersen; Kaja Borup Løvschall; Martin Tolstrup; Florian Kreppel; Jan Münch; Alexander N. Zelikin

Abstract Viral pathogens continue to constitute a heavy burden on healthcare and socioeconomic systems. Efforts to create antiviral drugs repeatedly lag behind the advent of pathogens and growing understanding is that broad‐spectrum antiviral agents will make strongest impact in future antiviral efforts. This work performs selection of synthetic polymers as novel broadly active agents and demonstrates activity of these polymers against Zika, Ebola, Lassa, Lyssa, Rabies, Marburg, Ebola, influenza, herpes simplex, and human immunodeficiency viruses. Results presented herein offer structure–activity relationships for these pathogens in terms of their susceptibility to inhibition by polymers, and for polymers in terms of their anionic charge and hydrophobicity that make up broad‐spectrum antiviral agents. The identified leads cannot be predicted based on prior data on polymer‐based antivirals and represent promising candidates for further development as preventive microbicides.


Antiviral Research | 2018

The molecular tweezer CLR01 inhibits Ebola and Zika virus infection

Annika Röcker; Janis A. Müller; Erik Dietzel; Mirja Harms; Franziska Krüger; Christian Heid; Andrea Sowislok; Camilla Frich Riber; Alexandra Kupke; Sina Lippold; Jens von Einem; Judith Beer; Bernd Knöll; Stephan Becker; Jonas Schmidt-Chanasit; Markus Otto; Olli Vapalahti; Alexander N. Zelikin; Gal Bitan; Thomas Schrader; Jan Münch

ABSTRACT Ebola (EBOV) and Zika viruses (ZIKV) are responsible for recent global health threats. As no preventive vaccines or antiviral drugs against these two re‐emerging pathogens are available, we evaluated whether the molecular tweezer CLR01 may inhibit EBOV and ZIKV infection. This small molecule has previously been shown to inactivate HIV‐1 and herpes viruses through a selective interaction with lipid‐raft‐rich regions in the viral envelope, which results in membrane disruption and loss of infectivity. We found that CLR01 indeed blocked infection of EBOV and ZIKV in a dose‐dependent manner. The tweezer inhibited infection of epidemic ZIKV strains in cells derived from the anogenital tract and the central nervous system, and remained antivirally active in the presence of semen, saliva, urine and cerebrospinal fluid. Our findings show that CLR01 is a broad‐spectrum inhibitor of enveloped viruses with prospects as a preventative microbicide or antiviral agent. HighlightsThe molecular tweezer CLR01 inhibits EBOV and ZIKV infection.ZIKV infection of cells derived from the anogenital tract and the central nervous system is blocked.Anti‐ZIKV activity is retained in semen, urine, saliva, and CSF.CLR01 represents a broad‐spectrum inhibitor of enveloped viruses with prospects as a microbicide or antiviral agent.


Journal of Controlled Release | 2018

Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects

Kaja Zuwala; Camilla Frich Riber; Kaja Borup Løvschall; Anna H.F. Andersen; Lise Sørensen; Paulina Gajda; Martin Tolstrup; Alexander N. Zelikin

&NA; Macromolecular (pro)drugs hold much promise as broad‐spectrum antiviral agents as either microbicides or carriers for intracellular delivery of antiviral drugs. Intriguing opportunity exists in combining the two modes of antiviral activity in the same polymer structure such that the same polymer acts as a microbicide and also serves to deliver the conjugated drug (ribavirin) into the cells. We explore this opportunity in detail and focus on the polymer backbone as a decisive constituent of such formulations. Fourteen polyanions (polycarboxylates, polyphosphates and polyphosphonates, and polysulfonates) were analyzed for blood pro/anti coagulation effects, albumin binding and albumin aggregation, inhibitory activity on polymerases, cytotoxicity, and anti‐inflammatory activity in stimulated macrophages. Ribavirin containing monomers were designed to accommodate the synthesis of macromolecular prodrugs with disulfide‐exchange triggered drug release. Kinetics of drug release was fast in all cases however enhanced hydrophobicity of the polymer significantly slowed release of ribavirin. Results of this study present a comprehensive view on polyanions as backbone for macromolecular prodrugs of ribavirin as broad‐spectrum antiviral agents. Graphical abstract Figure. No Caption available.


ACS Macro Letters | 2018

Long-Acting, Potent Delivery of Combination Antiretroviral Therapy

Anna H.F. Andersen; Camilla Frich Riber; Kaja Zuwala; Martin Tolstrup; Frederik Dagnæs-Hansen; Paul W. Denton; Alexander N. Zelikin


Current Opinion in Colloid and Interface Science | 2017

Recent advances in macromolecular prodrugs

Camilla Frich Riber; Alexander N. Zelikin

Collaboration


Dive into the Camilla Frich Riber's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge